About Symbiotec
Symbiotec is a company based in Indore (India) founded in 2002 was acquired by Rosewood Private Intvestments in December 2018. Symbiotec has raised $61.01 million across 4 funding rounds from investors including Actis, Franklin Templeton and British International Investment. The company has 1,822 employees as of May 31, 2025. Symbiotec offers products and services including Cortico-Steroid API, Steroid-Hormone API, and Intermediates. Symbiotec operates in a competitive market with competitors including Laurus Labs, Sterling Pharma Solutions, Provepharm Life Solutions, Jubilant Pharma and SeQuent, among others.
- Headquarter Indore, India
- Employees 1822 as on 31 May, 2025
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Symbiotec Pharmalab
-
Annual Revenue
$87.38 M (USD)26as on Mar 31, 2024
-
Net Profit
$12.25 M (USD)313as on Mar 31, 2024
-
EBITDA
$21.55 M (USD)137as on Mar 31, 2024
-
Total Equity Funding
$61.01 M (USD)
in 4 rounds
-
Latest Funding Round
$48 M (USD), Series C
Oct 13, 2013
-
Investors
Actis
& 8 more
-
Employee Count
1822
as on May 31, 2025
-
Acquired by
Rosewood Private Intvestments
(Dec 18, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Symbiotec
Symbiotec offers a comprehensive portfolio of products and services, including Cortico-Steroid API, Steroid-Hormone API, and Intermediates.
Active ingredients for corticosteroids in therapies like pain management
APIs for steroid hormones used in dermatology and pediatrics
Raw materials for API synthesis in pharmaceutical applications
People of Symbiotec
Unlock access to complete
Funding Insights of Symbiotec
Symbiotec has successfully raised a total of $61.01M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $48 million completed in October 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Symbiotec
Symbiotec has secured backing from 9 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include Actis, Franklin Templeton and British International Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sustainable infrastructure projects are invested in for essential services.
|
Locked | Locked | Locked | |
|
Government agency focused on small and medium-sized businesses
|
Locked | Locked | Locked | |
|
Investments in multiple sectors are managed by Soyumm Marketing.
|
Locked | Locked | Locked |
Investor details for Symbiotec
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Symbiotec
Investment portfolio details for Symbiotec
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Symbiotec
Detailed financials for Symbiotec
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Symbiotec Comparisons
Peer comparison for Symbiotec
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Symbiotec
Symbiotec operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Laurus Labs, Sterling Pharma Solutions, Provepharm Life Solutions, Jubilant Pharma and SeQuent, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical and biotechnology company
|
|
| Locked | Locked | Locked |
Contract development, manufacturing, and analytical services for APIs are offered.
|
|
| Locked | Locked | Locked |
APIs and drug products are developed and valorized in pharmaceuticals.
|
|
| Locked | Locked | Locked |
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company.
|
|
| Locked | Locked | Locked |
APIs are developed and manufactured for therapeutic areas.
|
Detailed competitors of Symbiotec
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Symbiotec
Complete news archive for Symbiotec
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Symbiotec
Symbiotec was founded in 2002 and raised its 1st funding round 5 years after it was founded.
Symbiotec is headquartered in Indore, India. It is registered at Indore, Madhya Pradesh, India.
Symbiotec is a funded company, having raised a total of $61.01M across 4 funding rounds to date.
As of May 31, 2025, the latest employee count at Symbiotec is 1,822.
Annual revenue of Symbiotec is $87.38M as on Mar 31, 2024.
Symbiotec was established in 2002 in Indore, India, as a manufacturer in the pharmaceutical sector. Non-sterile APIs and intermediates derived from steroid hormones are produced, targeting therapeutic areas such as gastrointestinal ailments, cardiovascular disease, pain management, pediatrics, anti-infectives, and dermatology. Regulatory-compliant solutions are offered, alongside operations in research and quality control laboratories.
Symbiotec's top competitors include Laurus Labs, Sterling Pharma Solutions and Provepharm Life Solutions.
Symbiotec offers Cortico-Steroid API, Steroid-Hormone API, and Intermediates.
Symbiotec has 9 investors. Key investors include Actis, Franklin Templeton, British International Investment, R S Shapeti, and Rakesh Jhunjhunwala.
The valuation of Symbiotec is $32.19M as of Mar 2013.